Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Globe Newswire•22/09/2026•08:30 ET
0
– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy
– Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome
Get started
Create a free account to read the full story and Whiz Insights.